Cite

    Gilligan, A. et al. (2018). Comparison of all-cause costs and healthcare resource use among patients with newly-diagnosed non-valvular atrial fibrillation newly treated with oral anticoagulants. Current medical research and opinion. pp. 285-295. [Online].